Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.

Hendricks WPD, Zismann V, Sivaprakasam K, Legendre C, Poorman K, Tembe W, Perdigones N, Kiefer J, Liang W, DeLuca V, Stark M, Ruhe A, Froman R, Duesbery NS, Washington M, Aldrich J, Neff MW, Huentelman MJ, Hayward N, Brown K, Thamm D, Post G, Khanna C, Davis B, Breen M, Sekulic A, Trent JM.

PLoS Genet. 2018 Sep 6;14(9):e1007589. doi: 10.1371/journal.pgen.1007589. eCollection 2018 Sep.

2.

Anthrax Toxin Receptor 1 Is Essential for Arteriogenesis in a Mouse Model of Hindlimb Ischemia.

Andersen NJ, Boguslawski EA, Naidu AS, Szot C, Bromberg-White JL, Kits K, Kuk CY, Holton LE, St Croix B, Chambers CM, Duesbery NS.

PLoS One. 2016 Jan 19;11(1):e0146586. doi: 10.1371/journal.pone.0146586. eCollection 2016.

3.

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.

Monsma DJ, Cherba DM, Eugster EE, Dylewski DL, Davidson PT, Peterson CA, Borgman AS, Winn ME, Dykema KJ, Webb CP, MacKeigan JP, Duesbery NS, Nickoloff BJ, Monks NR.

Am J Cancer Res. 2015 Mar 15;5(4):1507-18. eCollection 2015.

4.

Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts.

Andersen NJ, Boguslawski EB, Kuk CY, Chambers CM, Duesbery NS.

Int J Oncol. 2015 Jul;47(1):71-80. doi: 10.3892/ijo.2015.2989. Epub 2015 May 6.

5.

Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations.

Peacock JD, Dykema KJ, Toriello HV, Mooney MR, Scholten DJ 2nd, Winn ME, Borgman A, Duesbery NS, Hiemenga JA, Liu C, Campbell S, Nickoloff BP, Williams BO, Steensma M.

Am J Med Genet A. 2015 Jul;167(7):1429-35. doi: 10.1002/ajmg.a.37048. Epub 2015 Mar 21.

PMID:
25808193
6.

Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreous.

Bromberg-White JL, Glazer L, Downer R, Furge K, Boguslawski E, Duesbery NS.

Invest Ophthalmol Vis Sci. 2013 Oct 3;54(10):6472-80. doi: 10.1167/iovs.13-12518.

PMID:
24003089
7.

A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro.

Ding G, Chen X, Zhu J, Duesbery NS, Cheng X, Cao B.

Clin Dev Immunol. 2013;2013:475809. doi: 10.1155/2013/475809. Epub 2013 Jun 5.

8.

Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.

Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, Dawes MJ, Baker LH, Thomas DG, Kamstock DA, Kitchell BE, Furge KA, Duesbery NS.

Mol Cancer Ther. 2013 Sep;12(9):1701-14. doi: 10.1158/1535-7163.MCT-12-0893. Epub 2013 Jun 26.

9.

MEK genomics in development and disease.

Bromberg-White JL, Andersen NJ, Duesbery NS.

Brief Funct Genomics. 2012 Jul;11(4):300-10. doi: 10.1093/bfgp/els022. Epub 2012 Jun 29. Review.

10.

Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin.

Bromberg-White JL, Boguslawski E, Hekman D, Kort E, Duesbery NS.

Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):8979-92. doi: 10.1167/iovs.11-7651.

PMID:
21989728
11.

MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.

Lee CS, Dykema KJ, Hawkins DM, Cherba DM, Webb CP, Furge KA, Duesbery NS.

PLoS One. 2011 Feb 18;6(2):e17165. doi: 10.1371/journal.pone.0017165.

12.

Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.

Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS, Mitchell IC, Nwariaku F, Frankel AE.

Mol Cancer Ther. 2010 Jan;9(1):190-201. doi: 10.1158/1535-7163.MCT-09-0694. Epub 2010 Jan 6.

13.

Origins of cancer.

Duesbery NS, MacKeigan JP.

Oncogene. 2008 Dec;27 Suppl 2:S2. doi: 10.1038/onc.2009.347. No abstract available.

PMID:
19956176
14.

Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin.

Bromberg-White JL, Boguslawski E, Duesbery NS.

PLoS One. 2009 Sep 14;4(9):e6956. doi: 10.1371/journal.pone.0006956.

15.

Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.

Alfano RW, Leppla SH, Liu S, Bugge TH, Meininger CJ, Lairmore TC, Mulne AF, Davis SH, Duesbery NS, Frankel AE.

Mol Cancer Res. 2009 Apr;7(4):452-61. doi: 10.1158/1541-7786.MCR-08-0451.

16.

Pathophysiology of anthrax.

Frankel AE, Kuo SR, Dostal D, Watson L, Duesbery NS, Cheng CP, Cheng HJ, Leppla SH.

Front Biosci (Landmark Ed). 2009 Jan 1;14:4516-24. Review.

17.

Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.

Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Bromberg-White JL, Duesbery NS, Frankel AE.

Mol Cancer Ther. 2008 May;7(5):1218-26. doi: 10.1158/1535-7163.MCT-08-0024.

18.

Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways.

Bromberg-White JL, Duesbery NS.

Methods Enzymol. 2008;438:355-65. doi: 10.1016/S0076-6879(07)38025-7.

PMID:
18413261
19.

The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution.

Rouleau C, Menon K, Boutin P, Guyre C, Yoshida H, Kataoka S, Perricone M, Shankara S, Frankel AE, Duesbery NS, Vande Woude G, Biemann HP, Teicher BA.

Int J Oncol. 2008 Apr;32(4):739-48.

PMID:
18360701
20.

Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.

Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH, Duesbery NS.

Mol Cancer Ther. 2008 Mar;7(3):648-58. doi: 10.1158/1535-7163.MCT-07-2229. Epub 2008 Mar 4.

21.

Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.

Alfano RW, Leppla SH, Liu S, Bugge TH, Duesbery NS, Frankel AE.

Cell Cycle. 2008 Mar 15;7(6):745-9. Epub 2008 Jan 18. Review.

PMID:
18245947
22.

Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage.

Kuo SR, Willingham MC, Bour SH, Andreas EA, Park SK, Jackson C, Duesbery NS, Leppla SH, Tang WJ, Frankel AE.

Microb Pathog. 2008 Jun;44(6):467-72. doi: 10.1016/j.micpath.2007.12.001. Epub 2007 Dec 23.

PMID:
18222626
23.

Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.

Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH, Teh BT.

Cancer Res. 2008 Jan 1;68(1):81-8. doi: 10.1158/0008-5472.CAN-07-5311.

24.

Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor.

Depeille P, Young JJ, Boguslawski EA, Berghuis BD, Kort EJ, Resau JH, Frankel AE, Duesbery NS.

Clin Cancer Res. 2007 Oct 1;13(19):5926-34.

25.
26.

LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin.

Young JJ, Bromberg-White JL, Zylstra C, Church JT, Boguslawski E, Resau JH, Williams BO, Duesbery NS.

PLoS Pathog. 2007 Mar;3(3):e27.

27.

MKK signaling and vascularization.

Depeille PE, Ding Y, Bromberg-White JL, Duesbery NS.

Oncogene. 2007 Feb 26;26(9):1290-6. Review.

PMID:
17322914
28.

Cancer: biology and therapeutics--a tribute to George Vande Woude.

Duesbery NS, Teh BT.

Oncogene. 2007 Feb 26;26(9):1258-9. No abstract available.

PMID:
17322909
29.

Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.

Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS, Frankel AE.

Clin Cancer Res. 2006 Dec 15;12(24):7437-43.

30.

Xenopus tropicalis oocytes: more than just a beautiful genome.

Bodart JF, Duesbery NS.

Methods Mol Biol. 2006;322:43-53. Review.

PMID:
16739715
31.
32.

Differential roles of p39Mos-Xp42Mpk1 cascade proteins on Raf1 phosphorylation and spindle morphogenesis in Xenopus oocytes.

Bodart JF, Baert FY, Sellier C, Duesbery NS, Flament S, Vilain JP.

Dev Biol. 2005 Jul 15;283(2):373-83.

33.

Involvement of domain II in toxicity of anthrax lethal factor.

Liang X, Young JJ, Boone SA, Waugh DS, Duesbery NS.

J Biol Chem. 2004 Dec 10;279(50):52473-8. Epub 2004 Oct 1.

34.

Xp38gamma/SAPK3 promotes meiotic G(2)/M transition in Xenopus oocytes and activates Cdc25C.

Perdiguero E, Pillaire MJ, Bodart JF, Hennersdorf F, Frödin M, Duesbery NS, Alonso G, Nebreda AR.

EMBO J. 2003 Nov 3;22(21):5746-56.

35.

Novel protein targeted therapy of metastatic melanoma.

Frankel AE, Koo HM, Leppla SH, Duesbery NS, Vande Woude GF.

Curr Pharm Des. 2003;9(25):2060-6. Review.

PMID:
14552326
36.

Anthrax lethal factor proteolysis and inactivation of MAPK kinase.

Chopra AP, Boone SA, Liang X, Duesbery NS.

J Biol Chem. 2003 Mar 14;278(11):9402-6. Epub 2003 Jan 9.

37.

Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alpha.

Kim SO, Jing Q, Hoebe K, Beutler B, Duesbery NS, Han J.

J Biol Chem. 2003 Feb 28;278(9):7413-21. Epub 2002 Dec 17.

38.

Anthrax fusion protein therapy of cancer.

Frankel AE, Powell BL, Duesbery NS, Vande Woude GF, Leppla SH.

Curr Protein Pept Sci. 2002 Aug;3(4):399-407. Review.

PMID:
12370003
39.

Characterization of MPF and MAPK activities during meiotic maturation of Xenopus tropicalis oocytes.

Bodart JF, Gutierrez DV, Nebreda AR, Buckner BD, Resau JR, Duesbery NS.

Dev Biol. 2002 May 15;245(2):348-61.

PMID:
11977986
40.

Developmental biology: an arresting activity.

Duesbery NS, Vande Woude GF.

Nature. 2002 Apr 25;416(6883):804-5. No abstract available.

PMID:
11976667
41.

Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.

Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3052-7. Epub 2002 Feb 26.

42.

Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.

Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH, Vande Woude GF.

Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4089-94. Epub 2001 Mar 20.

43.

Anthrax toxins.

Duesbery NS, Vande Woude GF.

Cell Mol Life Sci. 1999 Sep;55(12):1599-609. Review.

PMID:
10526577
44.

Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.

Duesbery NS, Vande Woude GF.

J Appl Microbiol. 1999 Aug;87(2):289-93.

45.

MEK wars, a new front in the battle against cancer.

Duesbery NS, Webb CP, Vande Woude GF.

Nat Med. 1999 Jul;5(7):736-7. No abstract available.

PMID:
10395314
46.

Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes.

Duesbery NS, Vande Woude GF.

Biol Cell. 1998 Oct;90(6-7):461-6. Review.

PMID:
9923071
47.

Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF.

Science. 1998 May 1;280(5364):734-7.

48.

CENP-E is an essential kinetochore motor in maturing oocytes and is masked during mos-dependent, cell cycle arrest at metaphase II.

Duesbery NS, Choi T, Brown KD, Wood KW, Resau J, Fukasawa K, Cleveland DW, Vande Woude GF.

Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9165-70.

49.

Supplemental Content

Loading ...
Support Center